BioWorld

May 3, 2002

AVI Starting Avicine Phase III To Speed Approval Timeline

AVI BioPharma Inc. changed the course for its lead anticancer product, the vaccine Avicine, in an effort to shorten the route toward a possible FDA approval. (BioWorld Today) Read More

Syrrx Enters Deal To Provide Roche With Protein Structures

Demyelination Is Mycobacterium leprae’s Nerve Killer In Infectious And Neurodegenerative Diseases

Nyxis Getting Ready To Move Glyxins Family Into The Clinic

Other News To Note

Quarterly Earnings Reports

Today's news in brief

BioWorld

BioWorld briefs for Jan 28, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 28, 2026.

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

Muted and missing M&As: JPM deals absent in 2026

BioWorld

For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...